Stay updated with breaking news from Cort lane. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com upgraded shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a buy rating to a strong-buy rating in a research note published on Saturday morning. Several other equities research analysts have also commented on the stock. Truist Financial lifted their price target on shares of Corcept Therapeutics from $36.00 to $42.00 and gave the […] ....
C M Bidwell & Associates Ltd. bought a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the 3rd quarter, Holdings Channel reports. The fund bought 4,606 shares of the biotechnology company’s stock, valued at approximately $125,000. Several other hedge funds have also made changes to their positions in CORT. Linden […] ....
C M Bidwell & Associates Ltd. bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,606 shares of the biotechnology company’s stock, valued at approximately $125,000. Other hedge […] ....
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Sean Maduck sold 27,068 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.97, for a total transaction of $702,955.96. Following the sale, the insider now directly owns 74,455 shares of the company’s stock, […] ....
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Sean Maduck sold 27,068 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.97, for a total value of $702,955.96. Following the transaction, the insider now directly owns 74,455 shares in the company, valued at […] ....